Vol 70, No 7 (2012)
Invasive electrophysiology
Published online: 2012-07-18

open access

Page views 406
Article views/downloads 805
Get Citation

Connect on Social Media

Connect on Social Media

Cardioverter-defibrillator in the treatment of arrhythmia induced by trastuzumab used in the adjuvant setting in a patient with positive human epidermal growth factor receptor type-2 breast cancer

Grzegorz Piotrowski, Rafał Gawor, Robert Słomka, Maciej Banasiak, Paweł Strzelecki, Zenon Gawor, Piotr Potemski
DOI: 10.33963/v.kp.78857
Kardiol Pol 2012;70(7):756-757.

Abstract

A case of a 36-year old woman with HER2-positive early breast cancer treated with adjuvant trastuzumab left ventricle dysfunction and cardiac arrest in ventricular fibrillation mechanism is presented. After having been successfully resuscitated, trastuzumab therapy was withheld, pharmacotherapy (beta-blocker, ACE-I) implemented and ICD was implanted. Echocardiography performed 6 months later, revealed normal systolic function of the left ventricle. The patient died despite further oncologic treatment due to progression of the disease. The authors discuss the approach to this dramatic but lone cardiac side effect of trastuzumab treatment.

Article available in PDF format

View PDF (Polish) Download PDF file



Polish Heart Journal (Kardiologia Polska)